索引超出了数组界限。
[1] 皮益苑, 周爽, 简鸣, 等. LncRNA中miRNA海绵活性与肿瘤的研究进展[J]. 中南医学科学杂志, 2019, 47(3): 230-234.
[2] Chan LH, Wang W, Yeung W, et al. Hedgehog signaling induces osteosarcoma development through Yap1 and H19 overexpression[J]. Oncogene, 2014, 33(40): 4857-4866.
[3] 刘乙澍, 曲国蕃. 长链非编码RNA在骨肉瘤中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 266-270.
[4] 孙红, 张志奇, 傅明. 长链非编码RNA在骨关节炎与骨肿瘤领域的研究进展[J]. 中国骨与关节杂志, 2016, 5(5): 397-400.
[5] Deng R, Zhang J, Chen J. lncRNA SNHG1 negatively regulates miRNA-101-3p to enhance the expression of ROCK1 and promote cell proliferation, migration and invasion in osteosarcoma[J]. Int J mol med, 2019, 43(3): 1157-1166.
[6] Shi JJ, Michelle S, Yang Y, et al. Disruption of both ROCK1 and ROCK2 genes in cardiomyocytes promotes autophagy and reduces cardiac fibrosis during aging[J]. FASEB J, 2019, 33(6): 7348-7362.
[7] Zheng S, Jiang F, Ge D, et al. LncRNA SNHG3/miRNA-151a-3p/RAB22A axis regulates invasion and migration of osteosarcoma[J]. Biomed pharmacother, 2019, 112: 108695.
[8] Ju C, Zhou R, Sun J, et al. LncRNA SNHG5 promotes the progression of osteosarcoma by sponging the miR-212-3p/SGK3 axis[J]. Cancer cell int, 2018, 18: 141.
[9] Wang Z, Wang Z, Liu J, et al. Long non-coding RNA SNHG5 sponges miR-26a to promote the tumorigenesis of osteosarcoma by targeting ROCK1[J]. Biomed pharmacother, 2018, 107: 598-605.
[10] Ruan JW, Zheng LL, Hu N, et al. Long noncoding RNA SNHG6 promotes osteosarcoma cell proliferation through regulating p21 and KLF2[J]. Arch Biochem Biophys, 2018, 646: 128-136.
[11] Zhu X, Yang G, Xu J, et al. Silencing of SNHG6 induced cell autophagy by targeting miR-26a-5p/ULK1 signaling pathway in human osteosarcoma[J]. Cancer Cell Int, 2019, 19: 82.
[12] Zhang GD, Gai PZ, Liao GY, et al. LncRNA SNHG7 participates in osteosarcoma progression by down-regulating p53 via binding to DNMT1[J]. Eur Rev Med Pharmacol Sci, 2019, 23(9): 3602-3610.
[13] Xu N, Xu J, Zuo Z, et al. Downregulation of lncRNA SNHG12 reversed IGF1R-induced osteosarcoma metastasis and proliferation by targeting miR-195-5p[J]. Gene, 2020, 726: 144145.
[14] Hou XK, Mao JS. Long noncoding RNA SNHG14 promotes osteosarcoma progression via miR-433-3p/FBXO22 axis[J]. Biochem Biophys Res Commun, 2020, 523(3): 766-772.
[15] Wang X, Hu K, Chao Y, et al. LncRNA SNHG16 promotes proliferation, migration and invasion of osteosarcoma cells by targeting miR-1301/BCL9 axis[J]. Biomed pharmacother, 2019, 114: 108798.
[16] Zhang J, Ju C, Zhang W, et al. LncRNA SNHG20 is associated with clinical progression and enhances cell migration and invasion in osteosarcoma[J]. IUBMB life, 2018, 70(11): 1115-1121.
[17] Gozo MC, Aspuria PJ, Cheon DJ, et al. Foxc2 induces Wnt4 and Bmp4 expression during muscle regeneration and osteogenesis[J]. Cell Death Differ, 2013, 20(8): 1031-1042.
[18] 余铃, 高天, 张政佩, 等. 阿霉素通过激活 Notch 信号通路促进骨肉瘤细胞干性特性[J]. 中国肿瘤临床, 2017, 44(11): 527-531.
[19] 张义, 张擎柱, 谷锐, 等. lncRNA FOXC2-AS1逆转骨肉瘤细胞对阿霉素耐药性的影响[J]. 临床肿瘤学杂志, 2019, 24(5): 385-390.
[20] Zhang CL, Zhu KP, Ma XL. Antisense lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2[J]. Cancer Lett, 2017, 396: 66-75.
[21] 张浩萌, 王钧, 史迪, 等. 长链非编码RNA FOXD2-AS1在骨肉瘤细胞中的表达及功能[J]. 现代肿瘤医学, 2019, 27(9): 1465-1469.
[22] Ren Z, Hu Y, Li G, et al. HIF-1α induced long noncoding RNA FOXD2-AS1 promotes the osteosarcoma through repressing p21[J]. Biomed pharmacother, 2019, 117: 109104.
[23] Yang L, Ge D, Chen X, et al. FOXP4-AS1 participates in the development and progression of osteosarcoma by downregulating LATS1 via binding to LSD1 and EZH2[J]. Biochem Biophy Res Commun, 2018, 502(4): 493-500.
[24] Gu W, Zhang E, Song L, et al. Long noncoding RNA HOXD-AS1 aggravates osteosarcoma carcinogenesis through epigenetically inhibiting p57 via EZH2[J]. Biomed pharmacother, 2018, 106: 890-895.
[25] Qu Y, Zheng S, Kang M, et al. Knockdown of long non-coding RNA HOXD-AS1 inhibits the progression of osteosarcoma[J]. Biomed Pharmacother, 2018, 98: 899-906.
[26] 王宁, 朴成哲, 孟晓娜. 长链非编码RNA HOXD-AS1通过RUNX3促进骨肉瘤细胞增殖[J]. 解剖科学进展, 2018, 24(3): 281-284.
[27] Wang L, Wang L, Zhang X. Knockdown of lncRNA HOXA-AS2 inhibits viability, migration and invasion of osteosarcoma cellsby miR-124-3p/E2F3[J]. Onco Targets Ther, 2019, 12: 10851-10861.
[28] Zhang C, Hu Y, Wan J, et al. MicroRNA-124 suppresses the migration and invasion of osteosarcoma cells via targeting ROR2-mediated non-canonical Wnt signaling[J]. Oncol Rep, 2015, 34(4): 2195-2201.
[29] Wang L, Kang FB, Sun N, et al. The tumor suppressor miR-124 inhibits cell proliferation and invasion by targeting B7-H3 in osteosarcoma[J]. Tumour Biol, 2016, 37(11): 14939-14947.
[30] Zhou Y, Han Y, Zhang Z, et al. MicroRNA-124 upregulation inhibits proliferation and invasion of osteosarcoma cells by targeting sphingosine kinase 1[J]. Hum Cell, 2017, 30(1): 30-40.
[31] Meng Q, Zhang W, Xu X, et al. The effects of TRAF6 on proliferation, apoptosis and invasion in osteosarcoma are regulated by miR-124[J]. Int J Mol Med, 2018, 41(5): 2968-2976.
[32] Ma C, Han J, Dong D, et al. MicroRNA-152 suppresses human osteosarcoma cell proliferation and invasion by targeting E2F transcription factor 3[J]. Oncol Res, 2018, 26(5): 765-773.
[33] Wang Y, Zhang R, Cheng G, et al. Long non-coding RNA HOXA-AS2 promotes migration and invasion by acting as a ceRNA of miR-520c-3p in osteosarcoma cells[J]. Cell cycle, 2018, 17(13): 1637-1648.
[34] Cao K, Fang Y, Wang H, et al. The lncRNA HOXA11-AS regulates Rab3D expression by sponging miR-125a-5p promoting metastasis of osteosarcoma[J]. Cancer Manag Res, 2019, 11: 4505-4518.